232 related articles for article (PubMed ID: 38558735)
1. The Role of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapies in Early-Stage Breast Cancer: Current Practices, Treatment De-escalation, and Future Prospects.
Hashem M; Rehman S; Salhab M
Cureus; 2024 Feb; 16(2):e55230. PubMed ID: 38558735
[TBL] [Abstract][Full Text] [Related]
2. Review of the status of neoadjuvant therapy in HER2-positive breast cancer.
Dowling GP; Keelan S; Toomey S; Daly GR; Hennessy BT; Hill ADK
Front Oncol; 2023; 13():1066007. PubMed ID: 36793602
[TBL] [Abstract][Full Text] [Related]
3. HER2+ Early Breast Cancer: From Escalation via Targeted and Post-Neoadjuvant Treatment to De-Escalation.
Graeser M; Gluz O
Breast Care (Basel); 2023 Dec; 18(6):455-463. PubMed ID: 38125917
[TBL] [Abstract][Full Text] [Related]
4. Advances in neoadjuvant therapy for HER2-positive breast cancers: a narrative review.
Wang Q; Wang X; Yang Y
Gland Surg; 2022 Aug; 11(8):1415-1423. PubMed ID: 36082097
[TBL] [Abstract][Full Text] [Related]
5. Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer.
Hong J; Park YH
Ther Adv Med Oncol; 2022; 14():17588359221106564. PubMed ID: 35756967
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Therapy for HER2-positive Breast Cancer.
Wuerstlein R; Harbeck N
Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
[TBL] [Abstract][Full Text] [Related]
7. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
8. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy.
Foldi J; Rozenblit M; Park TS; Knowlton CA; Golshan M; Moran M; Pusztai L
Curr Treat Options Oncol; 2021 Jul; 22(9):79. PubMed ID: 34213636
[TBL] [Abstract][Full Text] [Related]
9. Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective.
McGee SF; Clemons M; Savard MF
Curr Oncol; 2022 Jun; 29(6):4125-4137. PubMed ID: 35735438
[TBL] [Abstract][Full Text] [Related]
10. Evolving standards of care and new challenges in the management of HER2-positive breast cancer.
Choong GM; Cullen GD; O'Sullivan CC
CA Cancer J Clin; 2020 Sep; 70(5):355-374. PubMed ID: 32813307
[TBL] [Abstract][Full Text] [Related]
11. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
[TBL] [Abstract][Full Text] [Related]
12. Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer.
Harbeck N
Breast; 2019 Nov; 48 Suppl 1():S97-S102. PubMed ID: 31839172
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications.
Pernas Simon S
Ther Adv Med Oncol; 2014 Sep; 6(5):210-21. PubMed ID: 25342988
[TBL] [Abstract][Full Text] [Related]
14. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract][Full Text] [Related]
15. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
16. De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer.
Tasoulis MK; Heil J; Kuerer HM
Curr Breast Cancer Rep; 2022; 14(4):135-141. PubMed ID: 35915668
[TBL] [Abstract][Full Text] [Related]
17. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.
Harbeck N
Breast; 2022 Mar; 62 Suppl 1(Suppl 1):S12-S16. PubMed ID: 35148934
[TBL] [Abstract][Full Text] [Related]
19. Association between tumor molecular subtype, clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy: potential implications for de-escalation of axillary surgery.
Hong J; Tong Y; He J; Chen X; Shen K
Ther Adv Med Oncol; 2021; 13():1758835921996673. PubMed ID: 33737963
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
